In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...
Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer ...
The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
The U.K.-based company released the data at Obesity Week, an event organized by the Obesity ... after investors were underwhelmed by early data from a trial of a weight-loss pill.
AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.
Cellular's schizophrenia drug meeting trial goals, Britain's new mpox variant detection, proposed UK smoking bans, challenges in weight-loss medication access, CVS Health's strategy adaptation, South ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback